Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0
|
作者：
Dickinson, Michael [1 ,2 ]
Carlo-Stella, Carmelo [3 ,4 ]
Morschhauser, Franck [5 ,6 ]
Bachy, Emmanuel [7 ]
Corradini, Paolo [8 ,9 ]
Iacoboni, Gloria [10 ]
Khan, Cyrus [11 ]
Wrobel, Thomasz [12 ]
Offner, Fritz [13 ]
Trneny, Marek [14 ]
Wu, Shang-Ju [15 ]
Cartron, Guillaume [16 ]
Hertzberg, Mark [17 ,18 ]
Sureda, Anna [19 ]
Perez-Callejo, David [20 ]
Lundberg, Linda [20 ]
Relf, James [21 ]
Clark, Emma [21 ]
Humphrey, Kathryn [21 ]
Hutchings, Martin [22 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Humanitas Univ, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Milan, Italy
[5] Hop Claude Huriez, Lille, France
[6] CHU Lille, Lille, France
[7] Ctr Hosp Lyon Sud, Lyon, France
[8] Univ Milan, Milan, Italy
[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Allegheny Hlth Network, Pittsburgh, PA USA
[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland
[13] Univ Ziekenhuis Gent, Ghent, Belgium
[14] Charles Univ Hosp, Prague, Czech Republic
[15] Natl Taiwan Univ Hosp, Taipei, Taiwan
[16] CHU Montpellier, Montpellier, France
[17] Prince Wales Hosp, Sydney, NSW, Australia
[18] Univ New South Wales, Sydney, NSW, Australia
[19] Inst Catala Oncol Hosp, Barcelona, Spain
[20] F Hoffmann La Roche Ltd, Basel, Switzerland
[21] Roche Prod Ltd, Welwyn Garden City, Herts, England
[22] Rigshosp, Copenhagen, Denmark
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-478
引用
收藏
页码：S435 / S435
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Westin, Jason
    Maris, Michael B.
    Jacobson, Caron A.
    Patel, Prapti
    Lakhani, Nehal
    Harb, Wael
    Patel-Donnelly, Dipti
    McCaul, Kelly
    Escobar, Carolina
    Klencke, Barbara
    Al-Katib, Ayad M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01): : 52 - 59
  • [42] Sequencing Therapies in Relapsed/ Refractory Large B-cell Lymphoma to Optimize the Chance of Cure
    Luttwak, Efrat
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S119 - S120
  • [43] Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
    Goto, Hideki
    Makita, Shinichi
    Kato, Koji
    Tokushige, Kota
    Fujita, Taizo
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (09) : 1736 - 1743
  • [44] Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma
    Ivanov, Vadim
    Coso, Diane
    Chetaille, Bruno
    Esterni, Benjamin
    Olive, Daniel
    Aurran-Schleinitz, Therese
    Schiano, Jean Marc
    Stoppa, Anne-Marie
    Broussais-Guillaumot, Florence
    Blaise, Didier
    Bouabdallah, Reda
    LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2508 - 2513
  • [45] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Bo Xu
    European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
  • [46] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
  • [47] Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
    Garcia-Sancho, Alejandro Martin
    Cabero, Almudena
    Gutierrez, Norma C.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [48] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Xu, Bo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
  • [49] A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
    Brooks, Taylor R.
    Caimi, Paolo F.
    BLOOD REVIEWS, 2024, 63
  • [50] FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kasamon, Yvette L.
    Price, Lauren S. L.
    Okusanya, Olanrewaju O.
    Richardson, Nicholas C.
    Li, Ruo-Jing
    Ma, Lian
    Wu, Yu-Te
    Theoret, Marc
    Pazdur, Richard
    Gormley, Nicole J.
    ONCOLOGIST, 2021, 26 (10): : 879 - 886
12345